New eye drop study reveals how fluid drains in healthy eyes
NCT ID NCT05938699
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study tested NCX 470 eye drops in 18 healthy adults to see how they change fluid dynamics inside the eye. Participants received either the active drop or a placebo for 8 days. The goal was to measure fluid production, drainage, and pressure. Results will help researchers understand how this treatment might work for glaucoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NCX 470 (nitric oxide-donating bimatoprost) eye drops
- What this could lead to
- If successful, this study could explain exactly how NCX 470 lowers eye pressure, supporting its development as a treatment for open-angle glaucoma.
- What could go wrong
- This was a small, early-stage study in healthy volunteers, not glaucoma patients. The results may not predict real-world effectiveness or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPEN-ANGLE GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye test match the gold standard for glaucoma?
- Which laser best tames glaucoma pressure?
- Could a single eye implant replace years of glaucoma drops?
- Eye implant could offer long-term pressure control for glaucoma patients
- Glaucoma implant MINIject put to the test in everyday eye clinics
- Glaucoma implant could replace daily eye drops